Delayed
Nasdaq
01:00:00 2024-07-03 pm EDT
|
5-day change
|
1st Jan Change
|
16.78
USD
|
+2.88%
|
|
+1.70%
|
+64.67%
|
Fiscal Period: December |
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
674.1
|
482.9
|
435.9
|
940
|
-
|
-
|
Enterprise Value (EV)
1 |
383.6
|
15.61
|
-31.13
|
308.4
|
380.8
|
440.4
|
P/E ratio
|
-10.2
x
|
4.43
x
|
-2.76
x
|
-5.42
x
|
-5.27
x
|
-5.41
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
35.6
x
|
-
|
-
|
501
x
|
81.1
x
|
32
x
|
EV / Revenue
|
20.2
x
|
-
|
-
|
165
x
|
32.9
x
|
15
x
|
EV / EBITDA
|
-5.65
x
|
0.11
x
|
0.16
x
|
-1.82
x
|
-2.44
x
|
-2.62
x
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
1.61
x
|
0.92
x
|
0.96
x
|
1.45
x
|
1.81
x
|
2.18
x
|
Nbr of stocks (in thousands)
|
43,685
|
45,772
|
42,781
|
57,634
|
-
|
-
|
Reference price
2 |
15.43
|
10.55
|
10.19
|
16.31
|
16.31
|
16.31
|
Announcement Date
|
3/17/22
|
3/9/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
18.94
|
-
|
-
|
1.875
|
11.59
|
29.42
|
EBITDA
1 |
-
|
-60.27
|
-67.9
|
144.7
|
-190.3
|
-169.1
|
-155.8
|
-168.4
|
EBIT
1 |
-22.27
|
-60.34
|
-67.95
|
144.6
|
-190.6
|
-183.8
|
-201.1
|
-213.1
|
Operating Margin
|
-
|
-
|
-358.73%
|
-
|
-
|
-9,803.97%
|
-1,734.73%
|
-724.28%
|
Earnings before Tax (EBT)
1 |
-
|
-59.46
|
-
|
151.3
|
-169.2
|
-161.2
|
-169.6
|
-176.9
|
Net income
1 |
-
|
-51.8
|
-65.57
|
111.2
|
-153.2
|
-164.6
|
-188.9
|
-192.5
|
Net margin
|
-
|
-
|
-346.14%
|
-
|
-
|
-8,777.16%
|
-1,629.85%
|
-654.37%
|
EPS
2 |
-1,127
|
-3.637
|
-1.520
|
2.380
|
-3.690
|
-3.009
|
-3.094
|
-3.016
|
Free Cash Flow
|
-
|
-29.78
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/2/20
|
3/30/21
|
3/17/22
|
3/9/23
|
3/14/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
2025 Q2
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-34.35
|
-32.66
|
239.7
|
-29.77
|
-32.61
|
-62.76
|
-37.6
|
-45.24
|
-45.48
|
-42.99
|
-45.14
|
-47.75
|
-50.01
|
-59
|
-62
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-
|
-
|
240.1
|
-27.41
|
-28.95
|
-58.14
|
-32.21
|
-39.18
|
-39.68
|
-37.34
|
-40.3
|
-42.46
|
-44.03
|
-59
|
-61.5
|
Net income
1 |
-32.51
|
-12.1
|
174.9
|
-24.8
|
-26.78
|
-57.96
|
-32.21
|
-39.18
|
-23.8
|
-37.15
|
-40.6
|
-43.56
|
-46.2
|
-59
|
-62
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EPS
2 |
-0.7400
|
-0.2700
|
3.770
|
-0.5400
|
-0.5900
|
-1.420
|
-0.8200
|
-0.9100
|
-0.5400
|
-0.8600
|
-0.7150
|
-0.7325
|
-0.7362
|
-0.8550
|
-0.8850
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/17/22
|
5/16/22
|
8/10/22
|
11/14/22
|
3/9/23
|
5/11/23
|
8/10/23
|
11/8/23
|
3/14/24
|
5/15/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
210
|
290
|
467
|
467
|
632
|
559
|
500
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-29.8
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-16.1%
|
23.2%
|
-31%
|
-27.5%
|
-23.1%
|
-29.1%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
-0.9200
|
9.590
|
11.50
|
10.60
|
11.30
|
9.000
|
7.470
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.01
|
-
|
1.13
|
0.21
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/30/21
|
3/17/22
|
3/9/23
|
3/14/24
|
-
|
-
|
-
|
Last Close Price
16.31
USD Average target price
33
USD Spread / Average Target +102.33% Consensus |
1st Jan change
|
Capi.
|
---|
| +64.67% | 940M | | +16.59% | 44.87B | | -10.62% | 37.8B | | +40.49% | 37.61B | | +29.92% | 31.32B | | -9.78% | 27.4B | | +12.34% | 26.32B | | +41.53% | 14.07B | | +31.49% | 12.5B | | -7.40% | 11.23B |
Other Biotechnology & Medical Research
|